TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Minimizing the Risk of Metachronous Adenomas of the Colorectum With Green Tea Extract -MIRACLE-
Brief Summary: This is a randomized, placebo controlled, multicentric trial to investigate the effect of diet supplementation with green tea extract containing 300mg epigallocatechin gallate (EGCG), the major polyphenol of green tea, on the recurrence of colon adenomas.


Options:
A: Arm Label: Polyphenon E Treatment; Type: ACTIVE_COMPARATOR; Interventions: Drug: Polyphenon E | Arm Label: Placebo Administration; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Polyphenon E; Assigned to Arm(s): Polyphenon E Treatment | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Administration
B: Arm Label: Arm I (FO, GT catechin extract); Type: EXPERIMENTAL; Interventions: Dietary Supplement: green tea catechin extract, Dietary Supplement: fish oil | Arm Label: ArmII (FO placebo, GT catechin extract); Type: EXPERIMENTAL; Interventions: Dietary Supplement: green tea catechin extract, Other: placebo | Arm Label: Arm III (FO, GT placebo); Type: EXPERIMENTAL; Interventions: Dietary Supplement: fish oil, Other: placebo | Arm Label: Arm IV (FO placebo, GT placebo); Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: green tea catechin extract; Assigned to Arm(s): Arm I (FO, GT catechin extract), ArmII (FO placebo, GT catechin extract) | Intervention Type: DIETARY_SUPPLEMENT; Name: fish oil; Assigned to Arm(s): Arm I (FO, GT catechin extract), Arm III (FO, GT placebo) | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm III (FO, GT placebo), Arm IV (FO placebo, GT placebo) | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm IV (FO placebo, GT placebo), ArmII (FO placebo, GT catechin extract)
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: GTE group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: GTE (green tea extract) | Intervention Type: DIETARY_SUPPLEMENT; Name: GTE (green tea extract); Assigned to Arm(s): GTE group
D: Arm Label: Green tea extract; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Green tea extract of Camellia Sinensis | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Green tea extract of Camellia Sinensis followed by placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Green tea extract of Camellia Sinensis; Assigned to Arm(s): Green tea extract | Intervention Type: DIETARY_SUPPLEMENT; Name: Green tea extract of Camellia Sinensis followed by placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Two Fixed Doses of OPDC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Polaris Trial
Brief Summary: To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who demonstrate an incomplete response to a prospective trial of the same assigned FDA approved ADT


Options:
A: Arm Label: Desvenlafaxine succinate sustained-release 25 mg; Type: EXPERIMENTAL; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR) | Arm Label: Desvenlafaxine succinate sustained-release 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Desvenlafaxine Succinate Sustained-Release (DVS SR) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release (DVS SR); Assigned to Arm(s): Desvenlafaxine succinate sustained-release 25 mg | Intervention Type: DRUG; Name: Desvenlafaxine Succinate Sustained-Release (DVS SR); Assigned to Arm(s): Desvenlafaxine succinate sustained-release 50 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: Phase B; Type: EXPERIMENTAL; Interventions: Drug: OPC-34712 + ADT, Drug: Placebo + ADT | Arm Label: Phase A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + ADT | Intervention Type: DRUG; Name: OPC-34712 + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase A
C: Arm Label: Tree Theme Method ® (TTM) intervention; Type: EXPERIMENTAL; Interventions: Other: Tree Theme Method ® (TTM) | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Tree Theme Method ® (TTM); Assigned to Arm(s): Tree Theme Method ® (TTM) intervention
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: OPC-34712, Drug: ADT | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: ADT | Intervention Type: DRUG; Name: OPC-34712; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: ADT; Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Two Fixed Doses of OPDC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Polaris Trial
Brief Summary: To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who demonstrate an incomplete response to a prospective trial of the same assigned FDA approved ADT


Options:
A: Arm Label: Phase B; Type: EXPERIMENTAL; Interventions: Drug: OPC-34712 + ADT, Drug: Placebo + ADT | Arm Label: Phase A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + ADT | Intervention Type: DRUG; Name: OPC-34712 + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase A
B: Arm Label: Phase B; Type: EXPERIMENTAL; Interventions: Drug: OPC-34712 + ADT, Drug: Placebo + ADT | Arm Label: Phase A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + ADT | Intervention Type: DRUG; Name: OPC-34712 + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase A
C: Arm Label: Lithium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Lithium | Arm Label: Quetiapine; Type: EXPERIMENTAL; Interventions: Drug: Quetiapine | Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): Quetiapine | Intervention Type: DRUG; Name: Lithium; Assigned to Arm(s): Lithium
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Cariprazine 1-2 mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Arm Label: Cariprazine 2-4.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Cariprazine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Cariprazine; Assigned to Arm(s): Cariprazine 1-2 mg, Cariprazine 2-4.5 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Pyxis Trial
Brief Summary: To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who demonstrate an incomplete response to a prospective trial of the same assigned FDA approved ADT


Options:
A: Arm Label: Be Well At Work intervention + IC; Type: EXPERIMENTAL; Interventions: Other: Veterans Work and Health Initiative | Arm Label: Integrated Care Only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Veterans Work and Health Initiative; Assigned to Arm(s): Be Well At Work intervention + IC
B: Arm Label: Phase B; Type: EXPERIMENTAL; Interventions: Drug: OPC-34712 + ADT, Drug: Placebo + ADT | Arm Label: Phase A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + ADT | Intervention Type: DRUG; Name: OPC-34712 + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase A
C: Arm Label: Care manager for depression; Type: EXPERIMENTAL; Interventions: Other: care manager for depression | Arm Label: Treatment As Usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: care manager for depression; Assigned to Arm(s): Care manager for depression
D: Intervention Type: DRUG; Name: DVS-SR 50 mg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: DVS-SR 100 mg; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of the Safety and Efficacy of Fixed Dose OPC-34712 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Pyxis Trial
Brief Summary: To compare the effect of OPC-34712 (brexpiprazole) to the effect of placebo (an inactive substance) as add on treatment to an assigned FDA approved antidepressant treatment (ADT) in patients with Major Depressive Disorder who demonstrate an incomplete response to a prospective trial of the same assigned FDA approved ADT


Options:
A: Arm Label: Vilazodone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vilazodone | Arm Label: Citalopram; Type: PLACEBO_COMPARATOR; Interventions: Drug: Citalopram | Intervention Type: DRUG; Name: Vilazodone; Assigned to Arm(s): Vilazodone | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): Citalopram
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo to citalopram, Drug: Placebo to vilazodone | Arm Label: Vilazodone 20 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone, Drug: Placebo to citalopram, Drug: Placebo to vilazodone | Arm Label: Vilazodone 40 mg/day; Type: EXPERIMENTAL; Interventions: Drug: Vilazodone, Drug: Placebo to citalopram, Drug: Placebo to vilazodone | Arm Label: Citalopram 40 mg/day; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo to vilazodone, Drug: Citalopram | Intervention Type: DRUG; Name: Vilazodone; Assigned to Arm(s): Vilazodone 20 mg/day, Vilazodone 40 mg/day | Intervention Type: DRUG; Name: Placebo to citalopram; Assigned to Arm(s): Placebo, Vilazodone 20 mg/day, Vilazodone 40 mg/day | Intervention Type: DRUG; Name: Placebo to vilazodone; Assigned to Arm(s): Citalopram 40 mg/day, Placebo, Vilazodone 20 mg/day, Vilazodone 40 mg/day | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): Citalopram 40 mg/day
C: Intervention Type: DRUG; Name: Quetiapine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Amitriptyline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Citalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Duloxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Fluoxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Paroxetine; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Sertraline; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Venlafaxine; Assigned to Arm(s): N/A
D: Arm Label: Phase B; Type: EXPERIMENTAL; Interventions: Drug: OPC-34712 + ADT, Drug: Placebo + ADT | Arm Label: Phase A; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo + ADT | Intervention Type: DRUG; Name: OPC-34712 + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase B | Intervention Type: DRUG; Name: Placebo + ADT; Assigned to Arm(s): Phase A

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Structured Multidisciplinary Intervention to Improve Quality of Life of Patients Receiving Active Oncological Treatment: A Randomized Trial
Brief Summary: This randomized clinical trial studies structured multidisciplinary intervention or standard medical care in improving quality of life (QOL) in patients receiving active cancer treatment. A structured multidisciplinary intervention may improve the QOL in patients receiving treatment for cancer. It is not yet known whether structured multidisciplinary intervention is more effective than standard medical care in improving QOL


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Other: exercise | Arm Label: B; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: exercise; Assigned to Arm(s): A
B: Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Study Group; Type: EXPERIMENTAL; Interventions: Other: Domiciliary exercises for the upper limbs | Intervention Type: OTHER; Name: Domiciliary exercises for the upper limbs; Assigned to Arm(s): Study Group
C: Arm Label: GROUP A (multidisciplinary intervention); Type: N/A; Interventions: Procedure: quality-of-life assessment, Behavioral: telephone-based intervention, Other: questionnaire administration, Other: counseling intervention, Behavioral: exercise intervention, Other: educational intervention | Arm Label: GROUP B (standard medical care); Type: N/A; Interventions: Procedure: quality-of-life assessment, Other: questionnaire administration, Behavioral: telephone-based intervention, Procedure: standard follow-up care | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): GROUP A (multidisciplinary intervention), GROUP B (standard medical care) | Intervention Type: BEHAVIORAL; Name: telephone-based intervention; Assigned to Arm(s): GROUP A (multidisciplinary intervention) | Intervention Type: OTHER; Name: questionnaire administration; Assigned to Arm(s): GROUP A (multidisciplinary intervention), GROUP B (standard medical care) | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): GROUP A (multidisciplinary intervention) | Intervention Type: BEHAVIORAL; Name: exercise intervention; Assigned to Arm(s): GROUP A (multidisciplinary intervention) | Intervention Type: OTHER; Name: educational intervention; Assigned to Arm(s): GROUP A (multidisciplinary intervention) | Intervention Type: BEHAVIORAL; Name: telephone-based intervention; Assigned to Arm(s): GROUP B (standard medical care) | Intervention Type: PROCEDURE; Name: standard follow-up care; Assigned to Arm(s): GROUP B (standard medical care)
D: Arm Label: Swallowing therapy & resistance training; Type: EXPERIMENTAL; Interventions: Behavioral: Swallowing therapy & resistance training | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Swallowing therapy & resistance training; Assigned to Arm(s): Swallowing therapy & resistance training

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long-Term Follow-up of Antithrombotic Management Patterns in Acute Coronary Syndrome Patients in Asia
Brief Summary: The purpose of this study is to describe the short-and long-tern (i.e. up to 2 years following the index event) AMPs in patients hospitalized for an acute coronary syndrome (i.e. STEMI or NSTE-ACS), and to document clinical outcomes, economic aspects and impact on quality of life of these AMPs in a 'real-life' setting.


Options:
A: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Rivaroxaban/Placebo | Arm Label: 003; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Rivaroxaban/Placebo; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 003 | Intervention Type: DRUG; Name: Rivaroxaban; Assigned to Arm(s): 001
B: Arm Label: 1; Type: N/A; Interventions: N/A
C: Arm Label: Dabigatran dose 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 2 | Arm Label: Warfarin; Type: ACTIVE_COMPARATOR; Interventions: Drug: warfarin | Arm Label: Dabigatran dose 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dabigatran dose 1 | Intervention Type: DRUG; Name: warfarin; Assigned to Arm(s): Warfarin | Intervention Type: DRUG; Name: Dabigatran dose 1; Assigned to Arm(s): Dabigatran dose 1 | Intervention Type: DRUG; Name: Dabigatran dose 2; Assigned to Arm(s): Dabigatran dose 2
D: Arm Label: Acute Coronary Syndrome; Type: N/A; Interventions: Other: Thrombin generation assays, TEG and GTT | Intervention Type: OTHER; Name: Thrombin generation assays, TEG and GTT; Assigned to Arm(s): Acute Coronary Syndrome

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Illness Management and Recovery (IMR) in Danish Community Mental Health Centres: Protocol of a Randomized, Assessor-blinded Multi-centre Clinical Trial of a Recovery-oriented Program for People with Schizophrenia or Bipolar Disorder
Brief Summary: The aim of this trial is to evaluate the effectiveness of the Illness Management and Recovery program for people diagnosed with schizophrenia or bipolar disorder in according to their level of functioning.


Options:
A: Arm Label: motivational interviewing; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing, Other: Treatment as usual | Arm Label: control group; Type: OTHER; Interventions: Other: Treatment as usual | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing; Assigned to Arm(s): motivational interviewing | Intervention Type: OTHER; Name: Treatment as usual; Assigned to Arm(s): control group, motivational interviewing
B: Arm Label: Standard Care; Type: PLACEBO_COMPARATOR; Interventions: Other: Standard Care | Arm Label: Contingency management for abstinence from drugs; Type: EXPERIMENTAL; Interventions: Behavioral: contingency management | Intervention Type: BEHAVIORAL; Name: contingency management; Assigned to Arm(s): Contingency management for abstinence from drugs | Intervention Type: OTHER; Name: Standard Care; Assigned to Arm(s): Standard Care
C: Arm Label: IMR program; Type: EXPERIMENTAL; Interventions: Behavioral: Illness Management and Recovery (IMR) | Arm Label: Treatment as usual; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Illness Management and Recovery (IMR); Assigned to Arm(s): IMR program
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Contingency Management | Arm Label: 2; Type: OTHER; Interventions: Behavioral: Non Contingent Control Condition | Intervention Type: BEHAVIORAL; Name: Contingency Management; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Non Contingent Control Condition; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Primary-school-based Study to Reduce Prevalence of Childhood Obesity in Terres de l'Ebre (Catalunya (Spain) - EDAL-Educació en Estils Saludables de Vida alimentació-2: Study Protocol for a Randomized Controlled Trial
Brief Summary: Our hypothesis is that a regular systematic educational intervention in primary school improves lifestyle choices and reduces obesity. As such, the aim of the study is to evaluate the effects of a 3-year school-based program of lifestyle improvement, including diet and physical activity, implemented by university students acting as "health promoting agents" (HPA) on the prevalence of obesity.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Teacher-Delivered Weight Control Intervention | Arm Label: 2; Type: OTHER; Interventions: Behavioral: Teacher-Delivered General Health Intervention | Intervention Type: BEHAVIORAL; Name: Teacher-Delivered Weight Control Intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Teacher-Delivered General Health Intervention; Assigned to Arm(s): 2
B: Arm Label: Behaviour; Type: EXPERIMENTAL; Interventions: Behavioral: Health Education and Physical activity program | Arm Label: Nutrition; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Health Education and Physical activity program, Dietary Supplement: Nutrition Program | Intervention Type: BEHAVIORAL; Name: Health Education and Physical activity program; Assigned to Arm(s): Behaviour, Nutrition | Intervention Type: DIETARY_SUPPLEMENT; Name: Nutrition Program; Assigned to Arm(s): Nutrition
C: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: lifestyle counseling | Intervention Type: BEHAVIORAL; Name: lifestyle counseling; Assigned to Arm(s): lifestyle counseling
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: The StepSmart Challenge | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: The StepSmart Challenge; Assigned to Arm(s): Intervention

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Primary-school-based Study to Reduce Prevalence of Childhood Obesity in Terres de l'Ebre (Catalunya (Spain) - EDAL-Educació en Estils Saludables de Vida alimentació-2: Study Protocol for a Randomized Controlled Trial
Brief Summary: Our hypothesis is that a regular systematic educational intervention in primary school improves lifestyle choices and reduces obesity. As such, the aim of the study is to evaluate the effects of a 3-year school-based program of lifestyle improvement, including diet and physical activity, implemented by university students acting as "health promoting agents" (HPA) on the prevalence of obesity.


Options:
A: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: lifestyle counseling | Intervention Type: BEHAVIORAL; Name: lifestyle counseling; Assigned to Arm(s): lifestyle counseling
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: 6 months of healthy physical activity | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: 6 months of healthy physical activity; Assigned to Arm(s): 1
C: Intervention Type: BEHAVIORAL; Name: Fat and carbohydrate controlled diet; Assigned to Arm(s): N/A
D: Arm Label: Active Intervention: Obesity Prevention; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy Families-Childhood Obesity Prevention and Oral Health | Arm Label: Alternative Intervention/control: Oral Health; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy Families-Childhood Obesity Prevention and Oral Health | Intervention Type: BEHAVIORAL; Name: Healthy Families-Childhood Obesity Prevention and Oral Health; Assigned to Arm(s): Active Intervention: Obesity Prevention, Alternative Intervention/control: Oral Health

Answer: A